Keating AT - Search Results

1

A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma.

Cheson BD, Bartlett NL, Vose JM, Lopez-Hernandez A, Seiz AL, Keating AT, Shamsili S, Papadopoulos KP. Cheson BD, et al. Among authors: keating at. Cancer. 2012 Jun 15;118(12):3128-34. doi: 10.1002/cncr.26510. Epub 2011 Oct 17. Cancer. 2012. PMID: 22006123 Free article. Clinical Trial.

2

A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma.

Papadopoulos KP, Lopez-Jimenez J, Smith SE, Steinberg J, Keating A, Sasse C, Jie F, Thyss A. Papadopoulos KP, et al. Leuk Lymphoma. 2016 Aug;57(8):1848-55. doi: 10.3109/10428194.2015.1113275. Epub 2016 Feb 9. Leuk Lymphoma. 2016. PMID: 26857688 Clinical Trial.

3

A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma.

Kudchadkar R, Ernst S, Chmielowski B, Redman BG, Steinberg J, Keating A, Jie F, Chen C, Gonzalez R, Weber J. Kudchadkar R, et al. Cancer Med. 2015 May;4(5):643-50. doi: 10.1002/cam4.363. Epub 2014 Dec 23. Cancer Med. 2015. PMID: 25533314 Free PMC article. Clinical Trial.

4

A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations.

Yu HA, Spira A, Horn L, Weiss J, West H, Giaccone G, Evans T, Kelly RJ, Desai B, Krivoshik A, Moran D, Poondru S, Jie F, Aoyama K, Keating A, Oxnard GR. Yu HA, et al. Clin Cancer Res. 2017 Dec 15;23(24):7467-7473. doi: 10.1158/1078-0432.CCR-17-1447. Epub 2017 Sep 27. Clin Cancer Res. 2017. PMID: 28954786 Free PMC article. Clinical Trial.

5

A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.

Kelly RJ, Thomas A, Rajan A, Chun G, Lopez-Chavez A, Szabo E, Spencer S, Carter CA, Guha U, Khozin S, Poondru S, Van Sant C, Keating A, Steinberg SM, Figg W, Giaccone G. Kelly RJ, et al. Ann Oncol. 2013 Oct;24(10):2601-2606. doi: 10.1093/annonc/mdt249. Epub 2013 Jul 14. Ann Oncol. 2013. PMID: 23857959 Free PMC article. Clinical Trial.

6

Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia.

Chen J, Pise-Masison CA, Shih JH, Morris JC, Janik JE, Conlon KC, Keating A, Waldmann TA. Chen J, et al. Blood. 2013 Mar 14;121(11):2029-37. doi: 10.1182/blood-2012-05-427773. Epub 2013 Jan 15. Blood. 2013. PMID: 23321252 Free PMC article.

7

Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.

Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, Patnaik A, Papadopoulos K, Takimoto C, Bartels P, Keating A, Antonia S. Tolcher AW, et al. J Clin Oncol. 2008 Nov 10;26(32):5198-203. doi: 10.1200/JCO.2008.17.2064. Epub 2008 Sep 29. J Clin Oncol. 2008. PMID: 18824702 Free PMC article. Clinical Trial.

8

Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer.

Clemens MR, Gladkov OA, Gartner E, Vladimirov V, Crown J, Steinberg J, Jie F, Keating A. Clemens MR, et al. Breast Cancer Res Treat. 2015 Jan;149(1):171-9. doi: 10.1007/s10549-014-3238-6. Epub 2014 Dec 30. Breast Cancer Res Treat. 2015. PMID: 25547219 Free PMC article. Clinical Trial.

9

A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer.

Tolcher AW, Quinn DI, Ferrari A, Ahmann F, Giaccone G, Drake T, Keating A, de Bono JS. Tolcher AW, et al. Ann Oncol. 2012 Apr;23(4):968-73. doi: 10.1093/annonc/mdr353. Epub 2011 Aug 22. Ann Oncol. 2012. PMID: 21859898 Free article. Clinical Trial.

10

BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer.

Benson AB 3rd, Kiss I, Bridgewater J, Eskens FA, Sasse C, Vossen S, Chen J, Van Sant C, Ball HA, Keating A, Krivoshik A. Benson AB 3rd, et al. Clin Cancer Res. 2016 Oct 15;22(20):5058-5067. doi: 10.1158/1078-0432.CCR-15-3117. Epub 2016 Jul 11. Clin Cancer Res. 2016. PMID: 27401244 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

10 results

Search Page